Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8168775 Compositions and methods for inhibiting expression of transthyretin

Patent 8168775 was granted and assigned to Alnylam Pharmaceuticals on May, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Alnylam Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Rene Alvarez0

Gregory Hinkle0

Qingmin Chen0

Stuart Milstein0

Dinah Wen-Yee Sah0

Date of Patent

May 1, 2012

Patent Application Number

12582669

Date Filed

October 20, 2009

Patent Citations Received

US Patent 12123034 Methods and compositions for modulating a genome

0

US Patent 11697812 Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA

0

US Patent 11919865 Processes for preparing AG-10, its intermediates, and salts thereof

0

US Patent 11959081 Transthyretin (TTR) iRNA compositions and methods of use thereof

0

US Patent 12005043 Formulations of AG10

0

US Patent 12024728 Methods and compositions for modulating a genome

0

0

US Patent 12070449 Methods of treating TTR amyloidosis using AG10

0

Patent Primary Examiner

Patent abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8168775 Compositions and methods for inhibiting expression of transthyretin

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.